API | rimeporide

rimeporide Report issue

Small molecule Experimental

AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW

Rimeporide is an experimental drug for the treatment of Duchenne muscular dystrophy, being developed by the EspeRare foundation. it has been granted orphan drug status by the European Medicines Agency. ^Wikipedia

Chemistry

SMILES: Cc1cc(S(C)(=O)=O)c(S(C)(=O)=O)cc1C(=O)NC(=N)N
InChIKey: GROMEQPXDKRRIE-UHFFFAOYSA-N
Mol. Mass: 333.39
ALogP: -0.57 Partition coefficient
ChEMBL Molecule:
rimeporide

More Chemistry

Pharmacology

Mechanism of Action:
- Sodium/hydrogen exchanger (Amphiuma tridactylum) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

rimeporide

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)

Muscular Dystrophy, Duchenne (Phase 1)

Overview

Highest Phase: Phase 1
# of Trials: 1
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue